Numinus Expands Natural Psychedelic Research with New Biosecurity License Post published:March 14, 2022 Post category:Press Release
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Post published:March 9, 2022 Post category:Press Release
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders Post published:February 28, 2022 Post category:Press Release
Numinus Appoints New Bioscience Advisors to Advance IP Development Post published:February 1, 2022 Post category:Press Release
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada Post published:January 27, 2022 Post category:Press Release
Nova Mentis and KGK Science Form Tactical Partnership Post published:January 27, 2022 Post category:Press Release
Numinus Wellness Inc. Graduates to the OTCQX Best Market Post published:January 26, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q1 2022 Results Post published:January 20, 2022 Post category:Press Release
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Post published:January 19, 2022 Post category:Press Release
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Post published:January 14, 2022 Post category:Press Release